The Fort Worth Press - Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement

USD -
AED 3.672504
AFN 65.000368
ALL 81.910403
AMD 376.168126
ANG 1.79008
AOA 917.000367
ARS 1431.790402
AUD 1.425923
AWG 1.8025
AZN 1.70397
BAM 1.654023
BBD 2.008288
BDT 121.941731
BGN 1.67937
BHD 0.375999
BIF 2954.881813
BMD 1
BND 1.269737
BOB 6.889932
BRL 5.217404
BSD 0.997082
BTN 90.316715
BWP 13.200558
BYN 2.864561
BYR 19600
BZD 2.005328
CAD 1.36855
CDF 2200.000362
CHF 0.77566
CLF 0.021803
CLP 860.890396
CNY 6.93895
CNH 6.929815
COP 3684.65
CRC 494.312656
CUC 1
CUP 26.5
CVE 93.82504
CZK 20.504104
DJF 177.555076
DKK 6.322204
DOP 62.928665
DZD 129.553047
EGP 46.73094
ERN 15
ETB 155.0074
EUR 0.846204
FJD 2.209504
FKP 0.738005
GBP 0.734457
GEL 2.69504
GGP 0.738005
GHS 10.957757
GIP 0.738005
GMD 73.000355
GNF 8752.167111
GTQ 7.647681
GYD 208.609244
HKD 7.81385
HNL 26.45504
HRK 6.376104
HTG 130.618631
HUF 319.703831
IDR 16855.5
ILS 3.110675
IMP 0.738005
INR 90.57645
IQD 1310.5
IRR 42125.000158
ISK 122.710386
JEP 0.738005
JMD 156.057339
JOD 0.70904
JPY 157.200504
KES 128.622775
KGS 87.450384
KHR 4033.00035
KMF 419.00035
KPW 900.002243
KRW 1463.803789
KWD 0.30721
KYD 0.830902
KZT 493.331642
LAK 21426.698803
LBP 89293.839063
LKR 308.47816
LRD 187.449786
LSL 16.086092
LTL 2.95274
LVL 0.60489
LYD 6.314009
MAD 9.185039
MDL 17.000296
MGA 4426.402808
MKD 52.129054
MMK 2100.00747
MNT 3580.70414
MOP 8.023933
MRU 39.850379
MUR 46.060378
MVR 15.450378
MWK 1737.000345
MXN 17.263604
MYR 3.947504
MZN 63.750377
NAD 16.086092
NGN 1366.980377
NIO 36.694998
NOK 9.690604
NPR 144.506744
NZD 1.661958
OMR 0.383441
PAB 0.997082
PEN 3.367504
PGK 4.275868
PHP 58.511038
PKR 278.812127
PLN 3.56949
PYG 6588.016407
QAR 3.64135
RON 4.310404
RSD 99.553038
RUB 76.792845
RWF 1455.283522
SAR 3.749738
SBD 8.058149
SCR 13.675619
SDG 601.503676
SEK 9.023204
SGD 1.272904
SHP 0.750259
SLE 24.450371
SLL 20969.499267
SOS 568.818978
SRD 37.818038
STD 20697.981008
STN 20.719692
SVC 8.724259
SYP 11059.574895
SZL 16.08271
THB 31.535038
TJS 9.342721
TMT 3.505
TND 2.847504
TOP 2.40776
TRY 43.612504
TTD 6.752083
TWD 31.590367
TZS 2577.445135
UAH 42.828111
UGX 3547.71872
UYU 38.538627
UZS 12244.069517
VES 377.985125
VND 25950
VUV 119.988021
WST 2.726314
XAF 554.743964
XAG 0.012866
XAU 0.000202
XCD 2.70255
XCG 1.797032
XDR 0.689923
XOF 554.743964
XPF 101.703591
YER 238.403589
ZAR 16.04457
ZMK 9001.203584
ZMW 18.570764
ZWL 321.999592
  • SCS

    0.0200

    16.14

    +0.12%

  • CMSD

    0.0600

    23.95

    +0.25%

  • BCC

    1.8700

    91.03

    +2.05%

  • GSK

    1.0600

    60.23

    +1.76%

  • BCE

    -0.4900

    25.08

    -1.95%

  • RIO

    2.2900

    93.41

    +2.45%

  • JRI

    0.0900

    12.97

    +0.69%

  • RBGPF

    0.1000

    82.5

    +0.12%

  • BTI

    0.8400

    62.8

    +1.34%

  • NGG

    1.1700

    88.06

    +1.33%

  • AZN

    5.8700

    193.03

    +3.04%

  • CMSC

    -0.0400

    23.51

    -0.17%

  • VOD

    0.4900

    15.11

    +3.24%

  • RYCEF

    0.2600

    16.88

    +1.54%

  • RELX

    -0.7100

    29.38

    -2.42%

  • BP

    0.8400

    39.01

    +2.15%

Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement
Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement

Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement

  • First sublingual pre-workout single-serving supplement that delivers 50mg of caffeine rapidly to the body, is now available to order via Aspire's new direct-to-consumer shopping experience

Text size:

ESTERO, FL / ACCESS Newswire / July 31, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending supplement delivery technology, today announced the rollout of its new e-commerce solution, buzzbomb.buzz with BUZZ BOMB™ as its featured launch product. This new seamless direct-to-consumer shopping experience allows consumers to order BUZZ BOMB™ on the Aspire platform and have them shipped directly to their door with access to exclusive promotions, and customer support. To celebrate the launch, customers who register for Aspire's e-commerce site will have first access to special pricing, free shipping offers, and other promotions. The site features an introductory sample pack of four flavors as well as 30-packs in various configurations.

"We are excited to launch our new BUZZ BOMB™ e-commerce website in the U.S., which marks a significant step forward for the brand and will provide consumers with a seamless and personalized shopping experience," said Kraig Higginson, Interim Chief Executive Officer of Aspire. "This launch enables us to offer our advanced sublingual pre-workout supplement-designed to help athletes and fitness enthusiasts maximize their performance potential -directly to customers across the nation and at a competitive price. Together with our significant presence and marketing plans at two of the largest fitness conventions in early August, we are confident that the launch of our e-commerce site will further accelerate the brand's growth among active and fitness-minded consumers, helping us achieve our goal of providing one of the most advanced caffeine delivery formulas on the market."

Featuring 50mg of caffeine and designed to support sustained energy and mental focus, BUZZ BOMB™ is bringing its unique delivery technology benefits to the multi-billion-dollar pre-workout market to help athletes and fitness enthusiasts maximize their performance potential. BUZZ BOMB™, offered in four flavors (Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha), provides nearly instant energy, in easy-to-use small sublingual packets, which can be taken right before and during work out as needed. Unlike pre-workout products that are mixed with water and taken well before a workout, BUZZ BOMB™ is sprinkled under the tongue-without any mixing with water or hassle--for immediate effect.

About the Aspire Targeted Oral Delivery Platform

Aspire's technology delivers fast-acting supplement formulations which have been developed by using our patent-pending methodology, and "trade secret" process. The technology's new mechanism of action allows for rapid sublingual absorption. The benefits of "rapid absorption" are to provide rapid impact in more precise quantities.

About Aspire Biopharma, Inc.

Headquartered in Estero, Fl., Aspire Biopharma has developed a disruptive technology that can deliver supplements and drugs rapidly and precisely. For more information, please visit www.aspirebiolabs.com.

Safe Harbor Statement

Certain statements made in this communication are "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as "estimate," "projects," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "would," "should," "future," "propose," "potential," "target," "goal," "objective," "outlook" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Aspire Biopharma Holdings, Inc.

Contact

PCG Advisory
Kevin McGrath
+1-646-418-7002
[email protected]

SOURCE: Aspire Biopharma Holdings, Inc.



View the original press release on ACCESS Newswire

M.Delgado--TFWP